These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 23483542)
21. Polyglutamine aggregation in Huntington and related diseases. Polling S; Hill AF; Hatters DM Adv Exp Med Biol; 2012; 769():125-40. PubMed ID: 23560308 [TBL] [Abstract][Full Text] [Related]
22. Identification of human proteins that modify misfolding and proteotoxicity of pathogenic ataxin-1. Petrakis S; Raskó T; Russ J; Friedrich RP; Stroedicke M; Riechers SP; Muehlenberg K; Möller A; Reinhardt A; Vinayagam A; Schaefer MH; Boutros M; Tricoire H; Andrade-Navarro MA; Wanker EE PLoS Genet; 2012; 8(8):e1002897. PubMed ID: 22916034 [TBL] [Abstract][Full Text] [Related]
23. AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models. Hong H; Koon AC; Chen ZS; Wei Y; An Y; Li W; Lau MHY; Lau KF; Ngo JCK; Wong CH; Au-Yeung HY; Zimmerman SC; Chan HYE J Biol Chem; 2019 Feb; 294(8):2757-2770. PubMed ID: 30593503 [TBL] [Abstract][Full Text] [Related]
24. The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster. Tsou WL; Ouyang M; Hosking RR; Sutton JR; Blount JR; Burr AA; Todi SV Neurobiol Dis; 2015 Oct; 82():12-21. PubMed ID: 26007638 [TBL] [Abstract][Full Text] [Related]
25. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Teixeira-Castro A; Ailion M; Jalles A; Brignull HR; Vilaça JL; Dias N; Rodrigues P; Oliveira JF; Neves-Carvalho A; Morimoto RI; Maciel P Hum Mol Genet; 2011 Aug; 20(15):2996-3009. PubMed ID: 21546381 [TBL] [Abstract][Full Text] [Related]
26. An apparent core/shell architecture of polyQ aggregates in the aging Caenorhabditis elegans neuron. Fisher RS; Jimenez RM; Soto E; Kalev D; Elbaum-Garfinkle S Protein Sci; 2021 Jul; 30(7):1482-1486. PubMed ID: 33966305 [TBL] [Abstract][Full Text] [Related]
27. Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia. Tower C; Fu L; Gill R; Prichard M; Lesort M; Sztul E Neurobiol Dis; 2011 Jan; 41(1):11-22. PubMed ID: 20732421 [TBL] [Abstract][Full Text] [Related]
28. The impact of ataxin-1-like histidine insertions on polyglutamine aggregation. Jayaraman M; Kodali R; Wetzel R Protein Eng Des Sel; 2009 Aug; 22(8):469-78. PubMed ID: 19541676 [TBL] [Abstract][Full Text] [Related]
29. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. Chai Y; Wu L; Griffin JD; Paulson HL J Biol Chem; 2001 Nov; 276(48):44889-97. PubMed ID: 11572863 [TBL] [Abstract][Full Text] [Related]
30. Ataxin-1 fusion partners alter polyQ lethality and aggregation. Rich T; Varadaraj A PLoS One; 2007 Oct; 2(10):e1014. PubMed ID: 17925862 [TBL] [Abstract][Full Text] [Related]
31. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases]. Nagai Y Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247 [TBL] [Abstract][Full Text] [Related]
32. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Zhang S; Binari R; Zhou R; Perrimon N Genetics; 2010 Apr; 184(4):1165-79. PubMed ID: 20100940 [TBL] [Abstract][Full Text] [Related]
33. Dynamics of a Protein Interaction Network Associated to the Aggregation of polyQ-Expanded Ataxin-1. Vagiona AC; Andrade-Navarro MA; Psomopoulos F; Petrakis S Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 32992839 [TBL] [Abstract][Full Text] [Related]
34. The Traditional Formula Kai-Xin-San Alleviates Polyglutamine-Mediated Neurotoxicity by Modulating Proteostasis Network in Xiao L; Li H; Tian J; Jin N; Zhang J; Yang F; Zhou L; Wang Q; Huang Z Rejuvenation Res; 2020 Jun; 23(3):207-216. PubMed ID: 31985332 [TBL] [Abstract][Full Text] [Related]
35. Nuclear inclusions of pathogenic ataxin-1 induce oxidative stress and perturb the protein synthesis machinery. Laidou S; Alanis-Lobato G; Pribyl J; Raskó T; Tichy B; Mikulasek K; Tsagiopoulou M; Oppelt J; Kastrinaki G; Lefaki M; Singh M; Zink A; Chondrogianni N; Psomopoulos F; Prigione A; Ivics Z; Pospisilova S; Skladal P; Izsvák Z; Andrade-Navarro MA; Petrakis S Redox Biol; 2020 May; 32():101458. PubMed ID: 32145456 [TBL] [Abstract][Full Text] [Related]
36. Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes. Ayyadevara S; Balasubramaniam M; Gao Y; Yu LR; Alla R; Shmookler Reis R Aging Cell; 2015 Feb; 14(1):35-48. PubMed ID: 25510159 [TBL] [Abstract][Full Text] [Related]
37. Polyglutamine expansion accelerates the dynamics of ataxin-1 and does not result in aggregate formation. Krol HA; Krawczyk PM; Bosch KS; Aten JA; Hol EM; Reits EA PLoS One; 2008 Jan; 3(1):e1503. PubMed ID: 18231590 [TBL] [Abstract][Full Text] [Related]
38. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730 [TBL] [Abstract][Full Text] [Related]
39. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. Matos CA; de Macedo-Ribeiro S; Carvalho AL Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957 [TBL] [Abstract][Full Text] [Related]
40. ATXN1 N-terminal region explains the binding differences of wild-type and expanded forms. Rocha S; Vieira J; Vázquez N; López-Fernández H; Fdez-Riverola F; Reboiro-Jato M; Sousa AD; Vieira CP BMC Med Genomics; 2019 Oct; 12(1):145. PubMed ID: 31655597 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]